
LONDON — In the booming field of weight loss drugs, Roche has been riding high in recent months, with back-to-back positive studies of two experimental medicines that sent the company’s shares up — and those of its rivals down.
But on Thursday, company executives faced an onslaught of questions from analysts during an earnings presentation about what could come next for the company’s weight loss drugs and how they would stand apart in the wildly competitive field. Analysts asked what made the Roche drug candidates different, and how the company saw its lane given that it’s years behind other drugmakers, some of which already have products on the market.
“It’s going to be a huge market,” said Roche CEO Thomas Schinecker, seemingly trying to reassure analysts that there would be plenty of demand for the company’s drugs.

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect